The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome
Cardiorenal syndrome (CRS) is defined as a disorder of the heart and kidney, in which acute or chronic injury of one organ may lead to acute or chronic dysfunction of the other. It is characterized by high morbidity and mortality, resulting in high economic costs and social burdens. However, there i...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2022.1008517/full |
| _version_ | 1797990836625997824 |
|---|---|
| author | Mengying Yao Yong Liu Mengjia Sun Shaozong Qin Wang Xin Xu Guan Bo Zhang Ting He Yinghui Huang |
| author_facet | Mengying Yao Yong Liu Mengjia Sun Shaozong Qin Wang Xin Xu Guan Bo Zhang Ting He Yinghui Huang |
| author_sort | Mengying Yao |
| collection | DOAJ |
| description | Cardiorenal syndrome (CRS) is defined as a disorder of the heart and kidney, in which acute or chronic injury of one organ may lead to acute or chronic dysfunction of the other. It is characterized by high morbidity and mortality, resulting in high economic costs and social burdens. However, there is currently no effective drug-based treatment. Emerging evidence implicates the involvement of mitophagy in the progression of CRS, including cardiovascular disease (CVD) and chronic kidney disease (CKD). In this review, we summarized the crucial roles and molecular mechanisms of mitophagy in the pathophysiology of CRS. It has been reported that mitophagy impairment contributes to a vicious loop between CKD and CVD, which ultimately accelerates the progression of CRS. Further, recent studies revealed that targeting mitophagy may serve as a promising therapeutic approach for CRS, including clinical drugs, stem cells and small molecule agents. Therefore, studies focusing on mitophagy may benefit for expanding innovative basic research, clinical trials, and therapeutic strategies for CRS. |
| first_indexed | 2024-04-11T08:42:46Z |
| format | Article |
| id | doaj.art-200b313af81348bda7e6890db87b061d |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-04-11T08:42:46Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-200b313af81348bda7e6890db87b061d2022-12-22T04:34:05ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2022-10-011310.3389/fphys.2022.10085171008517The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndromeMengying Yao0Yong Liu1Mengjia Sun2Shaozong Qin3Wang Xin4Xu Guan5Bo Zhang6Ting He7Yinghui Huang8Department of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Cardiology, Institute of Cardiovascular Diseases of PLA, The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaCardiorenal syndrome (CRS) is defined as a disorder of the heart and kidney, in which acute or chronic injury of one organ may lead to acute or chronic dysfunction of the other. It is characterized by high morbidity and mortality, resulting in high economic costs and social burdens. However, there is currently no effective drug-based treatment. Emerging evidence implicates the involvement of mitophagy in the progression of CRS, including cardiovascular disease (CVD) and chronic kidney disease (CKD). In this review, we summarized the crucial roles and molecular mechanisms of mitophagy in the pathophysiology of CRS. It has been reported that mitophagy impairment contributes to a vicious loop between CKD and CVD, which ultimately accelerates the progression of CRS. Further, recent studies revealed that targeting mitophagy may serve as a promising therapeutic approach for CRS, including clinical drugs, stem cells and small molecule agents. Therefore, studies focusing on mitophagy may benefit for expanding innovative basic research, clinical trials, and therapeutic strategies for CRS.https://www.frontiersin.org/articles/10.3389/fphys.2022.1008517/fullCRSCKDCVDtargeted-therapymitophagy |
| spellingShingle | Mengying Yao Yong Liu Mengjia Sun Shaozong Qin Wang Xin Xu Guan Bo Zhang Ting He Yinghui Huang The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome Frontiers in Physiology CRS CKD CVD targeted-therapy mitophagy |
| title | The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome |
| title_full | The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome |
| title_fullStr | The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome |
| title_full_unstemmed | The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome |
| title_short | The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome |
| title_sort | molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome |
| topic | CRS CKD CVD targeted-therapy mitophagy |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2022.1008517/full |
| work_keys_str_mv | AT mengyingyao themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT yongliu themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT mengjiasun themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT shaozongqin themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT wangxin themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT xuguan themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT bozhang themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT tinghe themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT yinghuihuang themolecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT mengyingyao molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT yongliu molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT mengjiasun molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT shaozongqin molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT wangxin molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT xuguan molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT bozhang molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT tinghe molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome AT yinghuihuang molecularmechanismsandinterventionstrategiesofmitophagyincardiorenalsyndrome |